Fei Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fei Yang has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Guojian Bao
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China
3 shared publicationsJialu Ding
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China
3 shared publicationsJiawu Yan
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China
3 shared publicationsMinglu Zhang
Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
3 shared publicationsRao Fu
Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
3 shared publications- Beicheng Sun
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230001, China; Innovative Institute of Tumor Immunity and Medicine (ITIM), Hefei, Anhui, China; Anhui Province Key Laboratory of Tumor Immune Microenvironment and Immunotherapy, Hefei, Anhui, China; Anhui Provincial Innovation Institute for Pharmaceutical Basic Research, Hefei, Anhui, 230001, China
2 shared publications
Latest Publications
- Open Access
- 21 August 2025
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 16, 1620552
Small nucleolar RNA SNORD13H suppresses tumor progression via FBL-dependent 2′-O-methylation in hepatocellular carcinoma
Introduction: Small nucleolar RNA (snoRNA) mediates RNA modifications, including 2′-O-methylation (Nm) and pseudouridine (Ψ), which has been proven to impact tumor progression. However, the role of snoRNA in the epigenetics of tumors remains poorly understood due to the lack of sufficiently effective experimental methods to identify snoRNA targets. Here, we identified SNORD13H, a C/D box snoRNA, as being downregulated in hepatocellular carcinoma (HCC), and its low expression was associated with HCC development.Methods: To elucidate specific roles of SNORD13H in HCC, we used a comprehensive array of methodologies, including flow cytometry, xenograft mouse model, reverse transcription at low dNTP concentration followed by PCR (RTL-P) assay, and surface sensing of translation (SUnSET) assay.Results: In this study, we first demonstrated that reduced SNORD13H serves as a biomarker for HCC, facilitating cellular proliferation. SNORD13H mediates 2′-O-methylations of 18S rRNA and RAS mRNA, thereby enhancing translation efficiency and regulating RAS protein levels in HCC. The diminution of SNORD13H activates the RAS pathway, contributing to the progression of HCC.Discussion: Our study establishes SNORD13H as a dual-function regulator in HCC progression. Furthermore, our findings indicate that SNORD13H is detectable in plasma, highlighting its potential utility in tumor screening.
- 21 August 2025
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 16, 1620552
Open AccessSmall nucleolar RNA SNORD13H suppresses tumor progression via FBL-dependent 2′-O-methylation in hepatocellular carcinoma
Introduction: Small nucleolar RNA (snoRNA) mediates RNA modifications, including 2′-O-methylation (Nm) and pseudouridine (Ψ), which has been proven to impact tumor progression. However, the role of snoRNA in the epigenetics of tumors remains poorly understood due to the lack of sufficiently effective experimental methods to identify snoRNA targets. Here, we identified SNORD13H, a C/D box snoRNA, as being downregulated in hepatocellular carcinoma (HCC), and its low expression was associated with HCC development.Methods: To elucidate specific roles of SNORD13H in HCC, we used a comprehensive array of methodologies, including flow cytometry, xenograft mouse model, reverse transcription at low dNTP concentration followed by PCR (RTL-P) assay, and surface sensing of translation (SUnSET) assay.Results: In this study, we first demonstrated that reduced SNORD13H serves as a biomarker for HCC, facilitating cellular proliferation. SNORD13H mediates 2′-O-methylations of 18S rRNA and RAS mRNA, thereby enhancing translation efficiency and regulating RAS protein levels in HCC. The diminution of SNORD13H activates the RAS pathway, contributing to the progression of HCC.Discussion: Our study establishes SNORD13H as a dual-function regulator in HCC progression. Furthermore, our findings indicate that SNORD13H is detectable in plasma, highlighting its potential utility in tumor screening.
- Open Access
- 1 March 2025
- Published by Science China Press., Co. Ltd. in Chinese Science Bulletin
Insights into the molecular regulatory mechanisms of tumor macropinocytosis
巨胞饮是一个在真核生物中高度保守的、依赖肌动蛋白和溶酶体的内吞途径,通过形成巨胞饮小体非选择性地摄取细胞外可溶性物质,这一过程在多种生物学功能中发挥重要作用,包括抗原递呈、细胞代谢调控以及药物递送等。近年来,巨胞饮因其在胰腺导管腺癌等恶性肿瘤发展和转移中的关键作用而受到广泛关注,阻断巨胞饮能显著抑制肿瘤发展,靶向巨胞饮治疗肿瘤具有重要的临床转化价值,有关肿瘤巨胞饮发生的分子调控机制研究取得了许多重要研究进展。本文在简要概述巨胞饮发生过程的基础上,综述并讨论了最近关于巨胞饮在肿瘤细胞或肿瘤相关成纤维细胞响应营养压力时的信号转导途径,其中包括EGFR-PAK途径、mTOR、Ca2+-CaMKK2-AMPK-RAC1 途径、Ca2+-ARHGEF2-RAC1 和DDR1-NF-κB-p62/SQSTM1-NRF2途径,抗氧化因子NRF2介导的巨胞饮转录调控机制,巨胞饮与另一营养获取途径细胞自噬的相互调控关系,以及新发现的巨胞饮相关蛋白,包括V-ATPase、SDC1、LYSET、TPC、TMEM206和Slc15A调控巨胞饮发生的作用和机制。此外,本文还讨论了未来巨胞饮在发生机制研究和抑制剂开发方面所面临的问题及可能的解决策略。理解肿瘤巨胞饮发生的分子调控机制对于建立靶向巨胞饮途径的抗肿瘤策略具有十分重要的意义。
- 1 March 2025
- Published by Science China Press., Co. Ltd. in Chinese Science Bulletin
Open AccessInsights into the molecular regulatory mechanisms of tumor macropinocytosis
巨胞饮是一个在真核生物中高度保守的、依赖肌动蛋白和溶酶体的内吞途径,通过形成巨胞饮小体非选择性地摄取细胞外可溶性物质,这一过程在多种生物学功能中发挥重要作用,包括抗原递呈、细胞代谢调控以及药物递送等。近年来,巨胞饮因其在胰腺导管腺癌等恶性肿瘤发展和转移中的关键作用而受到广泛关注,阻断巨胞饮能显著抑制肿瘤发展,靶向巨胞饮治疗肿瘤具有重要的临床转化价值,有关肿瘤巨胞饮发生的分子调控机制研究取得了许多重要研究进展。本文在简要概述巨胞饮发生过程的基础上,综述并讨论了最近关于巨胞饮在肿瘤细胞或肿瘤相关成纤维细胞响应营养压力时的信号转导途径,其中包括EGFR-PAK途径、mTOR、Ca2+-CaMKK2-AMPK-RAC1 途径、Ca2+-ARHGEF2-RAC1 和DDR1-NF-κB-p62/SQSTM1-NRF2途径,抗氧化因子NRF2介导的巨胞饮转录调控机制,巨胞饮与另一营养获取途径细胞自噬的相互调控关系,以及新发现的巨胞饮相关蛋白,包括V-ATPase、SDC1、LYSET、TPC、TMEM206和Slc15A调控巨胞饮发生的作用和机制。此外,本文还讨论了未来巨胞饮在发生机制研究和抑制剂开发方面所面临的问题及可能的解决策略。理解肿瘤巨胞饮发生的分子调控机制对于建立靶向巨胞饮途径的抗肿瘤策略具有十分重要的意义。
- Open Access
- 19 February 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (3) , 108330
Collagen remodeling-mediated signaling pathways and their impact on tumor therapy
- 19 February 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (3) , 108330
Open AccessCollagen remodeling-mediated signaling pathways and their impact on tumor therapy
- Open Access
- 18 September 2024
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 150 (9) , 1-14
HOXA9 promotes proliferation, metastasis and prevents apoptosis in hepatocellular carcinoma
Purpose This research aimed to evaluate the expression level of Homeobox A9 (HOXA9) and its role in tumorigenesis of hepatocellular carcinoma (HCC). Methods Bioinformatic analysis, qPCR and Western blot analysis of clinical samples were employed to evaluate mRNA and protein levels of HOXA9 in HCC patients and cell lines. In vitro cell proliferation, migration and invasion, cloning formation, xenograft tumor model, wound healing and apoptosis assays, RNA sequencing analysis of RPL38-silenced HCC-LM3 cells and qPCR, Western blot analysis were performed for validation. Analysis of HOXA9-related genes were conducted to identify their relationships between HOXA9. Results HOXA9 is dramatically upregulated in HCC. Upregulation of HOXA9 in HCC predicts poor survival of patients. Besides, HOXA9 promotes proliferation, metastasis and prevents apoptosis in HCC in vitro. In addition, HOXA9 controlled by Ribosomal protein RPL38 is upregulated in HCC. Bioinformatic analysis also indicated that HOXA9 is involved in the regulation of DNA methylation and immune infiltration in HCC. Conclusion HOXA9 is dramatically upregulated in hepatocellular carcinoma and predicts poor prognosis. Besides, HOXA9 promoted proliferation and metastasis and prevented apoptosis in vitro, which is regulated by Ribosomal protein RPL38 in HCC.
- 18 September 2024
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 150 (9) , 1-14
Open AccessHOXA9 promotes proliferation, metastasis and prevents apoptosis in hepatocellular carcinoma
Purpose This research aimed to evaluate the expression level of Homeobox A9 (HOXA9) and its role in tumorigenesis of hepatocellular carcinoma (HCC). Methods Bioinformatic analysis, qPCR and Western blot analysis of clinical samples were employed to evaluate mRNA and protein levels of HOXA9 in HCC patients and cell lines. In vitro cell proliferation, migration and invasion, cloning formation, xenograft tumor model, wound healing and apoptosis assays, RNA sequencing analysis of RPL38-silenced HCC-LM3 cells and qPCR, Western blot analysis were performed for validation. Analysis of HOXA9-related genes were conducted to identify their relationships between HOXA9. Results HOXA9 is dramatically upregulated in HCC. Upregulation of HOXA9 in HCC predicts poor survival of patients. Besides, HOXA9 promotes proliferation, metastasis and prevents apoptosis in HCC in vitro. In addition, HOXA9 controlled by Ribosomal protein RPL38 is upregulated in HCC. Bioinformatic analysis also indicated that HOXA9 is involved in the regulation of DNA methylation and immune infiltration in HCC. Conclusion HOXA9 is dramatically upregulated in hepatocellular carcinoma and predicts poor prognosis. Besides, HOXA9 promoted proliferation and metastasis and prevented apoptosis in vitro, which is regulated by Ribosomal protein RPL38 in HCC.
- Open Access
- 28 May 2024
- Published by Springer Nature in Cell & Bioscience
- Vol. 14 (1) , 1-10
Causal effect between gut microbiota and metabolic syndrome in European population: a bidirectional mendelian randomization study
Background: Observational studies have reported that gut microbiota composition is associated with metabolic syndrome. However, the causal effect of gut microbiota on metabolic syndrome has yet to be confirmed. Methods: We performed a bidirectional Mendelian randomization study to investigate the causal effect between gut microbiota and metabolic syndrome in European population. Summary statistics of gut microbiota were from the largest available genome-wide association study meta-analysis (n = 13,266) conducted by the MiBioGen consortium. The summary statistics of outcome were obtained from the most comprehensive genome-wide association studies of metabolic syndrome (n = 291,107). The inverse-variance weighted method was applied as the primary method, and the robustness of the results was assessed by a series of sensitivity analyses. Results: In the primary causal estimates, Actinobacteria (OR = 0.935, 95% CI = 0.878–0.996, P = 0.037), Bifidobacteriales (OR = 0.928, 95% CI = 0.868–0.992, P = 0.028), Bifidobacteriaceae (OR = 0.928, 95% CI = 0.868–0.992, P = 0.028), Desulfovibrio (OR = 0.920, 95% CI = 0.869–0.975, P = 0.005), and RuminococcaceaeUCG010 (OR = 0.882, 95% CI = 0.803–0.969, P = 0.009) may be associated with a lower risk of metabolic syndrome, while Lachnospiraceae (OR = 1.130, 95% CI = 1.016–1.257, P = 0.025), Veillonellaceae (OR = 1.055, 95% CI = 1.004–1.108, P = 0.034) and Olsenella (OR = 1.046, 95% CI = 1.009–1.085, P = 0.015) may be linked to a higher risk for metabolic syndrome. Reverse MR analysis demonstrated that abundance of RuminococcaceaeUCG010 (OR = 0.938, 95% CI = 0.886–0.994, P = 0.030) may be downregulated by metabolic syndrome. Sensitivity analyses indicated no heterogeneity or horizontal pleiotropy. Conclusions: Our Mendelian randomization study provided causal relationship between specific gut microbiota and metabolic syndrome, which might provide new insights into the potential pathogenic mechanisms of gut microbiota in metabolic syndrome and the assignment of effective therapeutic strategies.
- 28 May 2024
- Published by Springer Nature in Cell & Bioscience
- Vol. 14 (1) , 1-10
Open AccessCausal effect between gut microbiota and metabolic syndrome in European population: a bidirectional mendelian randomization study
Background: Observational studies have reported that gut microbiota composition is associated with metabolic syndrome. However, the causal effect of gut microbiota on metabolic syndrome has yet to be confirmed. Methods: We performed a bidirectional Mendelian randomization study to investigate the causal effect between gut microbiota and metabolic syndrome in European population. Summary statistics of gut microbiota were from the largest available genome-wide association study meta-analysis (n = 13,266) conducted by the MiBioGen consortium. The summary statistics of outcome were obtained from the most comprehensive genome-wide association studies of metabolic syndrome (n = 291,107). The inverse-variance weighted method was applied as the primary method, and the robustness of the results was assessed by a series of sensitivity analyses. Results: In the primary causal estimates, Actinobacteria (OR = 0.935, 95% CI = 0.878–0.996, P = 0.037), Bifidobacteriales (OR = 0.928, 95% CI = 0.868–0.992, P = 0.028), Bifidobacteriaceae (OR = 0.928, 95% CI = 0.868–0.992, P = 0.028), Desulfovibrio (OR = 0.920, 95% CI = 0.869–0.975, P = 0.005), and RuminococcaceaeUCG010 (OR = 0.882, 95% CI = 0.803–0.969, P = 0.009) may be associated with a lower risk of metabolic syndrome, while Lachnospiraceae (OR = 1.130, 95% CI = 1.016–1.257, P = 0.025), Veillonellaceae (OR = 1.055, 95% CI = 1.004–1.108, P = 0.034) and Olsenella (OR = 1.046, 95% CI = 1.009–1.085, P = 0.015) may be linked to a higher risk for metabolic syndrome. Reverse MR analysis demonstrated that abundance of RuminococcaceaeUCG010 (OR = 0.938, 95% CI = 0.886–0.994, P = 0.030) may be downregulated by metabolic syndrome. Sensitivity analyses indicated no heterogeneity or horizontal pleiotropy. Conclusions: Our Mendelian randomization study provided causal relationship between specific gut microbiota and metabolic syndrome, which might provide new insights into the potential pathogenic mechanisms of gut microbiota in metabolic syndrome and the assignment of effective therapeutic strategies.